Evidence map›Paper›PMID 38517893›Full record

ReviewCell reports2024

Studying CaMKII: Tools and standards.

Carolyn Nicole Brown, Karl Ulrich Bayer

Abstract readReview
In one paragraph

Review in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Wnt/CaOncology letters · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Carolyn Nicole BrownDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Karl Ulrich BayerDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address: ulli.bayer@cuanschutz.edu.

Funding

CaMKII substrate-selection in opposing forms of synaptic plasticityR01NS081248 · NINDS · UNIVERSITY OF COLORADO DENVER · PI K. Ulrich Bayer · 2013 to 2026
$4.9M
CaMKII nitrosylation in the age-related decline of synaptic plasticityR01AG067713 · NIA · UNIVERSITY OF COLORADO DENVER · PI BAYER, K. ULRICH · 2020 to 2024
$2.7M
CaMKII in global cerebral ischemia: mechanisms and therapeutic interventionR01NS118786 · NINDS · UNIVERSITY OF COLORADO DENVER · PI BAYER, K. ULRICH, HERSON, PACO S · 2021 to 2025
$1.9M
Molecular computation by the CaMKII holoenzymeF31NS129254 · NINDS · UNIVERSITY OF COLORADO DENVER · PI BROWN, CAROLYN NICOLE · 2022 to 2024
$112k
NIA NIH HHS R01 AG067713NINDS NIH HHS F31 NS129254NINDS NIH HHS R01 NS081248NINDS NIH HHS R01 NS118786
6 · The paper itself

Abstract

The Ca

Indexed as

Calcium-Calmodulin-Dependent Protein Kinase Type 2AnimalsCalciumHumansCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 2CaMKIICP: Neuroscienceinhibitorsmutantssensorstools

Identifiers

PMID38517893
PMCPMC11088445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.